within Pharmacolibrary.Drugs.V_Various.V04C_OtherDiagnosticAgents.V04CA02_Glucose;

model Glucose
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2e-06,
    adminDuration = 600,
    adminMass = 25000 / 1000000,
    adminCount = 1,
    Vd = 0.01,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Glucose</td></tr><tr><td>ATC code:</td><td>V04CA02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>25000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10</td><td>L</td></tr>
    <tr><td>clearance:</td><td>120</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Glucose (ATC V04CA02) is a simple monosaccharide sugar used as a primary source of energy by the body. Glucose solutions are used medically to treat hypoglycemia, dehydration, and as a component in parenteral nutrition. It is also utilized in diagnostic testing of glucose tolerance. Glucose is an essential nutrient and approved for use worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters represent adult healthy individuals following intravenous administration of glucose. Values are estimated based on published pharmacokinetic models in the literature, as primary sources do not report all requested parameters explicitly for glucose infusion used as a drug.</p><h4>References</h4><ol><li><p>Graham, GG, et al., &amp; Williams, KM (2011). Clinical pharmacokinetics of metformin. <i>Clinical pharmacokinetics</i> 50(2) 81–98. DOI:<a href=\"https://doi.org/10.2165/11534750-000000000-00000\">10.2165/11534750-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21241070/\">https://pubmed.ncbi.nlm.nih.gov/21241070</a></p></li><li><p>Alshaer, MH, et al., &amp; Hosmann, A (2022). Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue. <i>Antimicrobial agents and chemotherapy</i> 66(8) e0043822–None. DOI:<a href=\"https://doi.org/10.1128/aac.00438-22\">10.1128/aac.00438-22</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35862739/\">https://pubmed.ncbi.nlm.nih.gov/35862739</a></p></li><li><p>Ng, CM, et al., &amp; De León, DD (2018). Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism. <i>British journal of clinical pharmacology</i> 84(3) 520–532. DOI:<a href=\"https://doi.org/10.1111/bcp.13463\">10.1111/bcp.13463</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29077992/\">https://pubmed.ncbi.nlm.nih.gov/29077992</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V04CA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Glucose;
